[{"id":"4bc744c9-f84b-494d-8e5c-dc24132e3743","acronym":"Precision-T (PhIII component)","url":"https://clinicaltrials.gov/study/NCT05316701","created_at":"2022-04-07T12:57:08.884Z","updated_at":"2024-07-02T16:35:00.902Z","phase":"Phase 3","brief_title":"Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies","source_id_and_acronym":"NCT05316701 - Precision-T (PhIII component)","lead_sponsor":"Orca Biosystems, Inc.","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Orca-T"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 174","initiation":"Initiation: 06/21/2022","start_date":" 06/21/2022","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2027","study_completion_date":" 04/01/2027","last_update_posted":"2024-05-27"},{"id":"236e87b1-3a45-4987-8e83-19ff77105b1b","acronym":"SU-09142011-8407","url":"https://clinicaltrials.gov/study/NCT01660607","created_at":"2021-01-18T07:10:13.721Z","updated_at":"2024-07-02T16:35:17.716Z","phase":"Phase 1/2","brief_title":"Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell","source_id_and_acronym":"NCT01660607 - SU-09142011-8407","lead_sponsor":"Everett Meyer","biomarkers":" FLT3 • HLA-DRB1","pipe":" | ","alterations":" Chr t(9;11)","tags":["FLT3 • HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(9;11)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Orca-T"],"overall_status":"Completed","enrollment":" Enrollment 68","initiation":"Initiation: 12/01/2011","start_date":" 12/01/2011","primary_txt":" Primary completion: 12/20/2023","primary_completion_date":" 12/20/2023","study_txt":" Completion: 12/20/2023","study_completion_date":" 12/20/2023","last_update_posted":"2024-02-26"},{"id":"a371a01d-3ae1-4151-8cf6-c3f5a72a47d9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05507827","created_at":"2022-08-19T17:10:05.391Z","updated_at":"2024-07-02T16:35:18.561Z","phase":"Phase 1","brief_title":"Safety of Myeloablative Conditioning, Orca-T, and Allogeneic, Donor-Derived CD19/CD22-CAR (Chimeric Antigen Receptor) T Cells in Adults With B-cell Acute Lymphoblastic Leukemia (ALL)","source_id_and_acronym":"NCT05507827","lead_sponsor":"Dr. Melody Smith, MD, MS","biomarkers":" CD19 • KMT2A • CRLF2 • CD22 • HLA-DRB1 • HLA-B • HLA-C","pipe":" | ","alterations":" KMT2A rearrangement • MLL rearrangement • CD19 expression • CRLF2 rearrangement","tags":["CD19 • KMT2A • CRLF2 • CD22 • HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KMT2A rearrangement • MLL rearrangement • CD19 expression • CRLF2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Orca-T • firicabtagene autoleucel (CRG-022)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 08/18/2022","start_date":" 08/18/2022","primary_txt":" Primary completion: 01/01/2037","primary_completion_date":" 01/01/2037","study_txt":" Completion: 01/01/2037","study_completion_date":" 01/01/2037","last_update_posted":"2024-02-20"}]